News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
Serial 14-3-3η testing: informing RA flare and joint damage risk as you treat-to-target
Vancouver, BC – April 18, 2017. At the premier Asia-Pacific rheumatology conference, the Japan College of Rheumatology Annual Scientific Meeting (JCR), taking place in Fukuoka, Japan on April 20-22, international investigators from the United States, Canada, and...
Accelerating the Transformation of Patient Care
Please see the Genome BC news release from last week. Augurex is proud of and appreciates the ongoing support that we receive from provincial and federal government programs to expedite JOINTstat™ access to patients worldwide. Augurex is recognized as an emerging...
14-3-3η: Informing the RA Continuum of Care
14-3-3η Informs the RA Continuum of Care Vancouver, BC – October 28, 2016. At the world’s premier rheumatology conference, the American College of Rheumatology Annual Meeting (ACR) in Washington, DC, November 11-16, international investigators from Sweden, the United...
JOINTstat™ (14-3-3η); New Possibilities in RA
Augurex Life Sciences Corp. announces big leaps forward for applications of the JOINTstat™ (14-3-3η) blood test in rheumatoid arthritis (RA). Disease management is quickly moving upstream toward earlier identification and treatment, in some cases even pre-disease, and...
JOINTstat™ cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA)
Augurex is pleased to announce that the JOINTstat™ (14-3-3η) blood test has been cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA). The test is indicated for the diagnosis of rheumatoid arthritis (RA) and the assessment and monitoring...
Augurex Presenting at World Congress on Inflammation
At the 12th World Congress on Inflammation in Boston from August 8-12, Dr. Anthony Marotta will be co-chairing Symposium #29: Biomarkers in Inflammation: Focus on Rheumatoid Arthritis and will be delivering the following two presentations alongside presenter and...
JOINTstat™ – Expanding the Impact
Expanded Use Indications JOINTstat™, a clinically game-changing blood test for Rheumatoid Arthritis (RA), now has expanded use indications in Canada and the EU. This novel test, which measures a protein called 14-3-3η, was first indicated for diagnostic use in RA....
New Testing And Treatment Improves Outlook For Those With Rheumatoid Arthritis
PREVENTION AND TREATMENT If you have been experiencing a prolonged period of pain, tenderness and stiffness around your joints, you should get to a doctor — and make it fast. Please read the full article on the personalhealthnews.ca website here...
JOIN OUR WEBINAR: JOINTstat™ – A New Blood Test for Rheumatoid Arthritis Diagnosis
Canadian Rheumatologist Webinar You are invited to: Introducing JOINTstat™ (14-3-3η): A New Biomechanistic Marker for the Early Diagnosis and Prognosis of Rheumatoid Arthritis Presenter: Walter P. Maksymowych, MD F.R.C.P.(C) Professor and Medical Scientists in the...
Accelerating the Transformation of Patient Care
Please see the Genome BC news release from last week. Augurex is proud of and appreciates the ongoing support that we receive from provincial and federal government programs to expedite JOINTstat™ access to patients worldwide. Augurex is recognized as an emerging...
14-3-3η: Informing the RA Continuum of Care
14-3-3η Informs the RA Continuum of Care Vancouver, BC – October 28, 2016. At the world’s premier rheumatology conference, the American College of Rheumatology Annual Meeting (ACR) in Washington, DC, November 11-16, international investigators from Sweden, the United...
JOINTstat™ (14-3-3η); New Possibilities in RA
Augurex Life Sciences Corp. announces big leaps forward for applications of the JOINTstat™ (14-3-3η) blood test in rheumatoid arthritis (RA). Disease management is quickly moving upstream toward earlier identification and treatment, in some cases even pre-disease, and...
JOINTstat™ cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA)
Augurex is pleased to announce that the JOINTstat™ (14-3-3η) blood test has been cleared for clinical use in Australia by the Therapeutic Goods Administration (TGA). The test is indicated for the diagnosis of rheumatoid arthritis (RA) and the assessment and monitoring...
Augurex Presenting at World Congress on Inflammation
At the 12th World Congress on Inflammation in Boston from August 8-12, Dr. Anthony Marotta will be co-chairing Symposium #29: Biomarkers in Inflammation: Focus on Rheumatoid Arthritis and will be delivering the following two presentations alongside presenter and...
JOINTstat™ – Expanding the Impact
Expanded Use Indications JOINTstat™, a clinically game-changing blood test for Rheumatoid Arthritis (RA), now has expanded use indications in Canada and the EU. This novel test, which measures a protein called 14-3-3η, was first indicated for diagnostic use in RA....
New Testing And Treatment Improves Outlook For Those With Rheumatoid Arthritis
PREVENTION AND TREATMENT If you have been experiencing a prolonged period of pain, tenderness and stiffness around your joints, you should get to a doctor — and make it fast. Please read the full article on the personalhealthnews.ca website here...
JOIN OUR WEBINAR: JOINTstat™ – A New Blood Test for Rheumatoid Arthritis Diagnosis
Canadian Rheumatologist Webinar You are invited to: Introducing JOINTstat™ (14-3-3η): A New Biomechanistic Marker for the Early Diagnosis and Prognosis of Rheumatoid Arthritis Presenter: Walter P. Maksymowych, MD F.R.C.P.(C) Professor and Medical Scientists in the...
JOINTstat™ – Transforming RA Patient Management
LifeLabs Medical Laboratory Services, the country's largest provider of community laboratory services, yesterday announced the Canadian launch of JOINTstat™ (14-3-3η), a biomarker blood test that is providing transformational insights into autoimmune joint damage...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact